As FY25 draws to a close, India’s equity markets have showcased a dynamic performance across indices, sectors, and market caps. While large-caps witnessed moderate gains, mid- and small-cap stocks stole the spotlight with staggering rallies—though not without volatility. Here’s a breakdown of the key trends and takeaways from FY25
Nifty 50: Steady Gains Amid Selective Sell-offs
The benchmark Nifty 50 rose 5.60% this fiscal year, driven by heavyweight outperformers:
Top Gainers:
BEL: +51.25% (Defense sector boost)
Bharti Airtel: +40.3% (5G expansion)
M&M: +39% (SUV demand surge)
Top Losers:
IndusInd Bank: -58% (NPA concerns)
Jio Financial: -35% (Regulatory hurdles)
Tata Motors: -32% (Supply chain disruptions)
Midcap & Smallcap Mania: High Risk, High Reward
Nifty Midcap 100 surged 8.40%,
led by:
Mazagon Dock: +186% (Naval contracts)
BSE Ltd: +118% (Equity trading boom)
Paytm: +98.3% (Fintech recovery)
Losers:
VI (Vodafone Idea): -48% (Debt woes)
Ola Electric: -41% (EV subsidy cuts)
2. Nifty Smallcap 100 climbed 6.30%,
Dominated by:
PG Electro: +468.5% (Battery tech hype)
Garden Reach Shipbuilders: +122% (Govt tenders)
Godfrey Phillips: +118.5% (Tobacco demand)
Losers:
Sonata Software: -51% (IT spending slowdown)
Delhivery: -42% (Logistics cost pressures)
Sectoral Performance: Pharma Shines, Energy Struggles
Top Sectors:
Pharma: +11.20% (Chronic drug demand)
Metal: +10.80% (Infrastructure push)
Bank: +9.30% (Retail credit growth)
Laggards:
Energy: -13.10% (Renewable transition costs)
PSU Banks: -10.10% (Asset quality stress)
Realty: -4.50% (Unsold inventory glut)
Fund Flows & IPO Boom
FIIs withdrew ₹3,93,805 crore amid global uncertainty, while DIIs injected ₹5,99,495 crore, underscoring domestic confidence.
IPOs: 103 issues raised $2,11,127 crore, reflecting a buoyant primary market.
Key Takeaways
Domestic Resilience: DII inflows offset FII exits, stabilizing markets.
Smallcap Spectacle: Explosive rallies in stocks like PG Electro highlight retail investor frenzy but warrant caution.
Sector Rotation: Defensive sectors (Pharma) outperformed cyclical ones (Realty, Energy).
Disclaimer
The information provided here is for educational and informational purposes only. It does not constitute financial advice, nor should it be interpreted as a recommendation to buy, sell, or hold any securities. Market investments carry risks, including potential loss of principal. Readers are advised to consult certified financial advisors before making investment decisions. Past performance is not indicative of future results.